Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?

Patients with antiphospholipid syndrome (APS) are at increased risk of recurrent thromboembolic events due to the pathology of the disease. While prolonged anticoagulation is the treatment of choice for patients with thrombosis, much debate remains about the optimum intensity of anticoagulation. Ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Esther, Do, Tiffanie, Peacock, Katie, Takundwa, Prisca T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2016
Materias:
Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045335/
https://www.ncbi.nlm.nih.gov/pubmed/27725921
http://dx.doi.org/10.7759/cureus.765
_version_ 1782457099415977984
author Kim, Esther
Do, Tiffanie
Peacock, Katie
Takundwa, Prisca T
author_facet Kim, Esther
Do, Tiffanie
Peacock, Katie
Takundwa, Prisca T
author_sort Kim, Esther
collection PubMed
description Patients with antiphospholipid syndrome (APS) are at increased risk of recurrent thromboembolic events due to the pathology of the disease. While prolonged anticoagulation is the treatment of choice for patients with thrombosis, much debate remains about the optimum intensity of anticoagulation. Anticoagulation with warfarin has been shown to decrease rates of thrombosis recurrence, but definitive evidence regarding targeted therapy to an INR of moderate (2.0 - 3.0) or high (3.1 - 4.0) intensity is lacking. 
format Online
Article
Text
id pubmed-5045335
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-50453352016-10-10 Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events? Kim, Esther Do, Tiffanie Peacock, Katie Takundwa, Prisca T Cureus Rheumatology Patients with antiphospholipid syndrome (APS) are at increased risk of recurrent thromboembolic events due to the pathology of the disease. While prolonged anticoagulation is the treatment of choice for patients with thrombosis, much debate remains about the optimum intensity of anticoagulation. Anticoagulation with warfarin has been shown to decrease rates of thrombosis recurrence, but definitive evidence regarding targeted therapy to an INR of moderate (2.0 - 3.0) or high (3.1 - 4.0) intensity is lacking.  Cureus 2016-09-01 /pmc/articles/PMC5045335/ /pubmed/27725921 http://dx.doi.org/10.7759/cureus.765 Text en Copyright © 2016, Kim et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Rheumatology
Kim, Esther
Do, Tiffanie
Peacock, Katie
Takundwa, Prisca T
Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title_full Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title_fullStr Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title_full_unstemmed Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title_short Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
title_sort recommended therapeutic inr range for patients with antiphospholipid syndrome on warfarin anticoagulation: is moderate-intensity (inr 2.0 - 3.0) or high-intensity (inr 3.1 - 4.0) better for reducing risk of recurrent thromboembolic events?
topic Rheumatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045335/
https://www.ncbi.nlm.nih.gov/pubmed/27725921
http://dx.doi.org/10.7759/cureus.765
work_keys_str_mv AT kimesther recommendedtherapeuticinrrangeforpatientswithantiphospholipidsyndromeonwarfarinanticoagulationismoderateintensityinr2030orhighintensityinr3140betterforreducingriskofrecurrentthromboembolicevents
AT dotiffanie recommendedtherapeuticinrrangeforpatientswithantiphospholipidsyndromeonwarfarinanticoagulationismoderateintensityinr2030orhighintensityinr3140betterforreducingriskofrecurrentthromboembolicevents
AT peacockkatie recommendedtherapeuticinrrangeforpatientswithantiphospholipidsyndromeonwarfarinanticoagulationismoderateintensityinr2030orhighintensityinr3140betterforreducingriskofrecurrentthromboembolicevents
AT takundwapriscat recommendedtherapeuticinrrangeforpatientswithantiphospholipidsyndromeonwarfarinanticoagulationismoderateintensityinr2030orhighintensityinr3140betterforreducingriskofrecurrentthromboembolicevents

Ejemplares similares